Pipeline

Drug Development Pipeline

CompoundINDPh IPh IIPh IIINDAMarket
Rivoceranib/Apatinib/YN968D1(VEGFr)

 

 

 

 

 

China (Hengrui)

 

 

 

Global (LSK)

AL3810

 

 

 

China (Haihe)

AL3818 (VEGFr, FGFr)

 

 

 

 

 

China (CTTQ)

 

 

 

Global (Advenchen/CTTQ)

AL8326 (AuroraB, VEGFr, FGFr)

 

 

China (Advenchen)

AL2846 (c-Met)

 

China (CTTQ/Advenchen)

AL58805 (mTor)

 

China (Advenchen)

AL58922 (pi3k alpha/mTor)

IND enabling

YN968D1(Apatinib)
YN968D1 (Apatinib) has been marketed in China as of the end of 2014 by Hengrui, global development is by LSK BioPharma.

AL3810
Clinical development in China by Haihe Pharmaceuticals and is in Phase III.

AL3818
Our scientists have synthesized and discovered a series of novel small molecule PTK inhibitors. Phase II and III clinical trials are ongoing in US, Three oncology indications have been approved in China.

AL8326
AL8326 is an inhibitor of Aurora B, FGFr, and VEGFr.

Phase I/IIa clinical trial is ongoing in China.

AL2846
AL2846 is a c-Met receptor tyrosine kinase (RTK) inhibitor and it also inhibits other RTKs of Flt4, KDR, Axl and Ron.

Phase I clinical trial is ongoing in China.

AL58805 (mTor)
Phase I clinical trial in China. US IND end of 2020.

AL58922 (pi3k alpha/mTor)
The compound is in IND-enabling studies.